NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Motilal Oswal Raises BUY Rating on Canara HSBC Life Insurance

Canara HSBC Life Insurance (CANHLIFE) has reported a 12% year-over-year (YoY) growth in Annual Premium Equivalent (APE) to INR7b for the quarter, in line with expectations. The company's individual APE witnessed a 15% YoY growth, while the overall APE for FY26 grew by 20% YoY to approximately INR28b.

A significant contributor to the company's stellar performance was the growth in traditional products, which accounted for around 80% of the contributions. As a result, the company's Value of New Business (VNB) grew by a remarkable 49% YoY to INR2.1b, beating estimates by 35%. This led to a VNB margin of 30.5%, a significant increase from 23% in the fourth quarter of FY25. The company's VNB for FY26 grew by 41% YoY to INR6.3b, with the VNB margin expanding by 330 basis points YoY to 22.4%.

In light of the strong performance in the fourth quarter of FY26, Motilal Oswal has maintained its APE estimates and increased VNB margin estimates by 200 basis points each for FY27 and FY28. This has led to a 2% increase in the company's Enterprise Value (EV) estimates for FY27 and FY28. As a result, the research firm has reiterate its BUY rating on Canara HSBC Life Insurance, with a target price of INR180, based on 1.7x FY28E EV.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Company4QFY26 APE GrowthFY26 APE Growth4QFY26 VNB GrowthFY26 VNB Growth
Canara HSBC Life Insurance12%20%49%41%

Investor Takeaway

Investors should consider buying Canara HSBC Life Insurance with a target price of Rs 180.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.